Home Health Costs Topics

Health Costs

The MIDTERMS

Democrats Hold a Nearly 2-to-1 Advantage Over Republicans on Handling the Cost of Health Care

Poll: Cost of Health Care and Gas Top Voters’ Midterm Concerns; Democrats Hold Significant Advantage on Health Care Costs and Cost of Living 

With the 2026 midterms about a month away, health care costs remain tied with gas as voters’ top midterm concerns and the Democrats hold a clear edge over the Republicans Party on who voters trust to handle many top electoral issues, including the cost of health care and the cost of living. Two-thirds of U.S. adults now favor Medicare-for-all, a new high in KFF Polling, but support shifts when competing claims from critics and proponents are heard.

New and noteworthy

Health System Tracker

Is This A Healthcare Economy?

Health care employment has grown faster than other sectors of the economy, with jobs in physician offices, hospitals, outpatient care centers, home health, and other settings increasing over the past year even as the rest of the job market plateaued. 

U.S. Health Spending Is Expected to Reach $9 Trillion by 2034

How Much is Health Spending Expected to Grow?

This chart collection explores how much health spending is expected to grow in the coming years, with a look at growth in prescription drug spending, out-of-pocket spending, and related trends.

How TrumpRx Brand-Name Drug Prices Compare

TrumpRx prices for brand-name drugs are about as likely to be higher as lower compared to average prices in other wealthy countries, according to an analysis that compares 32 brand-name drugs.

Latest News

More KFF Health News

Stay informed.

Get KFF's latest on Health Costs

Stay informed.

Get KFF's latest on Health Costs

View the Latest: Health Costs

Filter

List Grid

1,001-1,010 of 1,626 results

  • Analysis: Prices for Many Brand-Name TrumpRx Drugs Are Cheaper than the Average Price in Other Wealthy Countries, But Are Almost as Likely To Be More Expensive

    News Release

    Consumers who buy brand-name prescription drugs without an available generic or biosimilar at the prices available through the new TrumpRx website are about as likely to pay more as pay less for those drugs relative to the publicly listed prices available in other comparatively wealthy countries, a new KFF analysis finds. The Trump administration has promoted the TrumpRx website as a way for consumers to get the lowest prices for prescription medications in the world, drawing on…

  • Why We Are Stuck with Prior Authorization Review

    From Drew Altman

    Prior authorization review frustrates patients and physicians, but we likely can’t just eliminate it. In his new column, President and CEO Dr. Drew Altman discusses why, and why the focus is now instead on “doing it smarter.” Altman writes: “A proposal to eliminate prior authorization altogether could be the single most tangible and popular health reform idea a candidate could make. But, in our fragmented health system, with no great way to control costs or…

  • How TrumpRx Brand-Name Drug Prices Compare to Other Countries

    Issue Brief

    TrumpRx prices for brand-name drugs are about as likely to be higher as lower compared to average prices in other wealthy countries, according to an analysis that compares 32 brand-name drugs (without generics or biosimilars) on the TrumpRx website with publicly available prices in one or more of 11 OECD member countries.

  • Health Care Experiences of Native Hawaiian or Pacific Islander Adults

    Issue Brief

    A new issue brief based on focus groups conducted by KFF among NHPI adults living in Hawaii and the continental U.S. highlights barriers NHPI people face when accessing health care, including geographic isolation, limited system capacity, and language access. In their own words, participants describe both positive and negative experiences in health care settings and discuss concerns about mental health in their communities.

  • Health Spending Issues to Watch This Year

    Issue Brief

    KFF and the Peterson Center on Healthcare examine market trends contributing to rising health costs and identify several potential federal and state policy issues to watch throughout 2025, including high-cost drugs, federal funding cuts, and workforce shortages.

  • Most of the Public Oppose Major Federal Cuts to Health Agencies and Programs and Say They Have Been Made “Recklessly”

    News Release

    As the Trump administration and Congress pursue broad cuts to federal health agencies and budgets, most of the public, including some Republicans, oppose deep budget and staffing cuts to federal health programs and agencies, a new KFF Health Tracking Poll finds. Across a range of questions, large majorities of Democrats and independents oppose the Trump administration’s major cuts to federal health agencies and programs, while Republicans are more supportive. Those who identify with President Trump’s…